Tymara B. Berry

Pediatric Endocrinology

100 Madison Ave Ste 53
Morristown, NJ 07960

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Overall survival and long-term outcomes from the randomized, double-blind, placebo-controlled, phase III IMerge trial of imetelstat for lower-risk myelodysplastic syndromes.

Overall survival and long-term outcomes from the randomized, double-blind, placebo-controlled, phase III IMerge trial of imetelstat for lower-risk myelodysplastic syndromes.

Journal: Haematologica

Published: June 22, 2026

Association between treatment-emergent cytopenias and clinical responses to imetelstat in lower-risk myelodysplastic syndromes.

Association between treatment-emergent cytopenias and clinical responses to imetelstat in lower-risk myelodysplastic syndromes.

Journal: Blood cancer journal

Published: February 03, 2026

Increased duration of time without transfusion reliance with imetelstat vs placebo in the phase 3 IMerge trial.

Increased duration of time without transfusion reliance with imetelstat vs placebo in the phase 3 IMerge trial.

Journal: Blood neoplasia

Published: October 15, 2025

Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study.

Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study.

Journal: Haematologica

Published: August 21, 2025

No Effect of Immunogenicity on Pharmacokinetics, Efficacy, and Safety of the Oligonucleotide Telomerase Inhibitor Imetelstat in Lower-Risk Myelodysplastic Syndromes.

No Effect of Immunogenicity on Pharmacokinetics, Efficacy, and Safety of the Oligonucleotide Telomerase Inhibitor Imetelstat in Lower-Risk Myelodysplastic Syndromes.

Journal: Clinical and translational science

Published: August 01, 2025

Clinical outcomes and safety in patients with lower-risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trial.

Clinical outcomes and safety in patients with lower-risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trial.

Journal: British journal of haematology

Published: July 29, 2025

Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat.

Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat.

Journal: Leukemia

Published: June 23, 2025

Low Proarrhythmic Risk of Imetelstat, a Novel Oligonucleotide Telomerase Inhibitor: A Translational Analysis.

Low Proarrhythmic Risk of Imetelstat, a Novel Oligonucleotide Telomerase Inhibitor: A Translational Analysis.

Journal: Clinical and translational science

Published: October 02, 2024

Imetelstat, a novel, first-in-class telomerase inhibitor: Mechanism of action, clinical, and translational science.

Imetelstat, a novel, first-in-class telomerase inhibitor: Mechanism of action, clinical, and translational science.

Journal: Clinical and translational science

Published: August 29, 2024

Population pharmacokinetics of imetelstat, a first-in-class oligonucleotide telomerase inhibitor.

Population pharmacokinetics of imetelstat, a first-in-class oligonucleotide telomerase inhibitor.

Journal: CPT: pharmacometrics & systems pharmacology

Published: November 09, 2023

Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial.

Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial.

Journal: Lancet (London, England)

Published: June 30, 2023

Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design.

Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design.

Journal: Future oncology (London, England)

Published: May 05, 2022

Showing 1-12 of 15

Last Updated: 09/26/2026